Vancouver-based biotechnology company Absci reported $1.27 million in revenues in its second quarter financial report. That’s down from the second quarter in 2023, when the company brought in $3.37 million in revenue.
The company reported a $24.75 million net loss, of 22 cents per diluted share. That’s a smaller net loss than the company reported in the second quarter of 2023, which was $41.72 million, or 45 cents per diluted share.
The company trades on the Nasdaq as ABSI. Its stock closed at $3.73 per share Wednesday, down from its Tuesday close of $3.88 per share.
